Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Filip van den Bosch

Showing results (141-150 of 193) with videos related to

Pageof 20
Sort By:
Rheumatology (Oxford, England)|January 11, 2025
Long-term safety and efficacy of bimekizumab in axial spondyloarthritis: 2-year results from two phase 3 studiesXenofon Baraliakos, Atul Deodhar, Désirée van der Heijde, et al.
Annals of the Rheumatic Diseases|December 4, 2020
Upadacitinib for psoriatic arthritis refractory to biologics: SELECT-PsA 2Philip J Mease, Apinya Lertratanakul, Jaclyn K Anderson, et al.
Lancet (London, England)|November 17, 2019
Efficacy and safety of upadacitinib in patients with active ankylosing spondylitis (SELECT-AXIS 1): a multicentre, randomised, double-blind, placebo-controlled, phase 2/3 trialDésirée van der Heijde, In-Ho Song, Aileen L Pangan, et al.
RMD Open|August 25, 2025
Efficacy of risankizumab across GRAPPA domains in psoriatic arthritis: a pooled analysis of patients from the phase 3 KEEPsAKE 1 and 2 studiesLaura C Coates, Ricardo Blanco, Frank Behrens, et al.
RMD Open|July 27, 2022
Upadacitinib in active ankylosing spondylitis: results of the 2-year, double-blind, placebo-controlled SELECT-AXIS 1 study and open-label extensionDésirée van der Heijde, Atul Deodhar, Walter P Maksymowych, et al.
Rheumatology and Therapy|October 1, 2025
Efficacy and Safety of Risankizumab for Active Psoriatic Arthritis: 196-Week Results from the KEEPsAKE 1 and KEEPsAKE 2 Randomized Clinical TrialsAndrew Östör, Filip Van den Bosch, Kim Papp, et al.
The Journal of Rheumatology|July 17, 2020
Ixekizumab Improves Functioning and Health in the Treatment of Radiographic Axial Spondyloarthritis: Week 52 Results from 2 Pivotal StudiesUta Kiltz, James Cheng-Chung Wei, Désirée van der Heijde, et al.
Arthritis Research & Therapy|September 19, 2006
Four-year follow-up of infliximab therapy in rheumatoid arthritis patients with long-standing refractory disease: attrition and long-term evolution of disease activityBert Vander Cruyssen, Stijn Van Looy, Bart Wyns, et al.
Arthritis Research & Therapy|February 5, 2025
Upadacitinib in active non-radiographic axial spondyloarthritis: 2-year data from the phase 3 SELECT-AXIS 2 studyFilip Van den Bosch, Atul Deodhar, Denis Poddubnyy, et al.
The Journal of Rheumatology|May 5, 2009
Etanercept in the longterm treatment of patients with ankylosing spondylitisBen Dijkmans, Paul Emery, Markku Hakala, et al.
Pageof 20

Showing results (141-150 of 193) with videos related to

Sort By:
Pageof 20
Rheumatology (Oxford, England)|January 11, 2025
Long-term safety and efficacy of bimekizumab in axial spondyloarthritis: 2-year results from two phase 3 studiesXenofon Baraliakos, Atul Deodhar, Désirée van der Heijde, et al.
Annals of the Rheumatic Diseases|December 4, 2020
Upadacitinib for psoriatic arthritis refractory to biologics: SELECT-PsA 2Philip J Mease, Apinya Lertratanakul, Jaclyn K Anderson, et al.
Lancet (London, England)|November 17, 2019
Efficacy and safety of upadacitinib in patients with active ankylosing spondylitis (SELECT-AXIS 1): a multicentre, randomised, double-blind, placebo-controlled, phase 2/3 trialDésirée van der Heijde, In-Ho Song, Aileen L Pangan, et al.
RMD Open|August 25, 2025
Efficacy of risankizumab across GRAPPA domains in psoriatic arthritis: a pooled analysis of patients from the phase 3 KEEPsAKE 1 and 2 studiesLaura C Coates, Ricardo Blanco, Frank Behrens, et al.
RMD Open|July 27, 2022
Upadacitinib in active ankylosing spondylitis: results of the 2-year, double-blind, placebo-controlled SELECT-AXIS 1 study and open-label extensionDésirée van der Heijde, Atul Deodhar, Walter P Maksymowych, et al.
Rheumatology and Therapy|October 1, 2025
Efficacy and Safety of Risankizumab for Active Psoriatic Arthritis: 196-Week Results from the KEEPsAKE 1 and KEEPsAKE 2 Randomized Clinical TrialsAndrew Östör, Filip Van den Bosch, Kim Papp, et al.
The Journal of Rheumatology|July 17, 2020
Ixekizumab Improves Functioning and Health in the Treatment of Radiographic Axial Spondyloarthritis: Week 52 Results from 2 Pivotal StudiesUta Kiltz, James Cheng-Chung Wei, Désirée van der Heijde, et al.
Arthritis Research & Therapy|September 19, 2006
Four-year follow-up of infliximab therapy in rheumatoid arthritis patients with long-standing refractory disease: attrition and long-term evolution of disease activityBert Vander Cruyssen, Stijn Van Looy, Bart Wyns, et al.
Arthritis Research & Therapy|February 5, 2025
Upadacitinib in active non-radiographic axial spondyloarthritis: 2-year data from the phase 3 SELECT-AXIS 2 studyFilip Van den Bosch, Atul Deodhar, Denis Poddubnyy, et al.
The Journal of Rheumatology|May 5, 2009
Etanercept in the longterm treatment of patients with ankylosing spondylitisBen Dijkmans, Paul Emery, Markku Hakala, et al.
Pageof 20